Clinical Observation of Jiawei Xiaoyaosan in Treating Liver Depression and Spleen Deficiency Type 2 Diabetes with Emotional Disorder

Fang-fang LI; Xue-dong KANG

doi:10.13422/j.cnki.syfjx.20190116

您当前的位置：

首页 >

文章列表页 >

Clinical Observation of Jiawei Xiaoyaosan in Treating Liver Depression and Spleen Deficiency Type 2 Diabetes with Emotional Disorder

Clinic | 更新时间：2021-02-09

- Clinical Observation of Jiawei Xiaoyaosan in Treating Liver Depression and Spleen Deficiency Type 2 Diabetes with Emotional Disorder
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 2, Pages: 134-138(2019)
- 作者机构：
  
  1.甘肃中医药大学，兰州　 730000；
  2.甘肃中医药大学　附属医院，兰州　 730020
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20190116
  CLC： R22; R242; R2-031; R287
- Received：16 May 2018，
  
  Published Online：19 October 2018，
  
  Published：20 January 2019
- 稿件说明：
移动端阅览
Fang-fang LI, Xue-dong KANG. Clinical Observation of Jiawei Xiaoyaosan in Treating Liver Depression and Spleen Deficiency Type 2 Diabetes with Emotional Disorder[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(2): 134-138.
DOI：

Fang-fang LI, Xue-dong KANG. Clinical Observation of Jiawei Xiaoyaosan in Treating Liver Depression and Spleen Deficiency Type 2 Diabetes with Emotional Disorder[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(2): 134-138. DOI： 10.13422/j.cnki.syfjx.20190116.

摘要

目的：

观察加味逍遥散治疗肝郁脾虚型2型糖尿病伴焦虑、抑郁情绪障碍患者的临床疗效。

方法：

选取符合纳入标准的肝郁脾虚型2型糖尿病伴焦虑、抑郁情绪障碍患者76例，随机分为对照组和治疗组，各38例。对照组给予基础药物二甲双胍缓释片联合黛力新治疗，治疗组在对照组的基础上联合加味逍遥散治疗。观察用药前后患者空腹血糖(fasting plasma glucose，FPG)，餐后2 h血糖(2 hours postprandial blood glucose，2 hPG)，糖化血红蛋白(haemoglobin A1c，HbA1c)，空腹血清胰岛素(FINS)水平及服糖后30 min血清胰岛素(30 min INS)水平，汉密尔顿抑郁量表评分(HAMD)，汉密尔顿焦虑量表评分(HAMA)等指标的变化。

结果：

与本组治疗前比较，两组患者FPG，2 hPG，HbA1c水平均明显降低(

0.05)，FINS水平显著下降(

0.01)，服糖后30 min INS水平明显升高(

0.05)，HAMD评分，HAMA评分明显降低(

0.05)；治疗后与对照组比较，治疗组患者FBG，2 hPG，HbA1c水平均显著降低(

0.01)，治疗组FINS水平明显降低(

0.05)，服糖后30 min INS水平明显升高(

0.05)，治疗组HAMD，HAMA评分显著降低(

0.01)，两组不良反应无明显差异。

结论：

加味逍遥散联合基础用药可以明显减轻肝郁脾虚型2型糖尿病伴情绪障碍患者的抑郁、焦虑程度，降低患者血糖、糖化血红蛋白，降低空腹胰岛素，升高服糖30 min INS水平，其作用可能与改善此类患者焦虑、抑郁等不良情绪有关。

Abstract

Objective:

To observe the clinical efficacy of Jiawei Xiaoyaosan for patients with anxiety and depression in type 2 diabetes with liver depression and spleen deficiency.

Method:

The 76 eligible patients with anxiety and depression in type 2 diabetes with liver depression and spleen deficiency were randomly divided into two groups: control group (38 cases) and treatment group (38 cases). In control group

the basic medicines metformin sustained-release tablets combined with deanxit were given; based on the treatment in control group

the patients in treatment additionally received Jiawei Xiaoyaosan. The changes of fasting plasma glucose (FPG)

2 hours postprandial blood glucose (2 hPG)

haemoglobin A1c (HbA1c)

fasting insulin (FINS) and serum insulin levels 30 minutes after glucose intake (30 min INS)

Hamilton depression scale (HAMD)

Hamilton anxiety scale (HAMA) and so on were observed and compared.

Result:

As compared with those before treatment

the levels of FPG

2 hPG and HbA1c were decreased significantly (

0.05)

fasting serum insulin levels were significantly decreased (

0.01)

30 min INS levels were increased (

0.05); HAMD and HAMA scores were significantly decreased (

0.05). After treatment

the levels of FPG

2 hPG and HbA1c in the treatment group were significantly lower than those in control group (

0.01)

and the FINS level in treatment group was lower (

0.05) while 30 min INS level was higher than those in control group (

0.05); in addition

the HAMD and HAMA scores in the treatment group were significantly lower than those in control group (

0.01)

but there was no significant difference in adverse reactions between two groups.

Conclusion:

Jiawei Xiaoyaosan combined with basic medication can significantly reduce depression and anxiety in patients with type 2 diabetes mellitus of liver depression and spleen deficiency

reduce blood glucose

glycosylated hemoglobin

decrease fasting insulin and increase 30 min INS level. The effect may be related to the improvement of anxiety

depression and other adverse emotions in these patients.

关键词

Keywords

references

史秀明，徐国良，黎宇，等．中药治疗糖尿病的研究进展 [J]. 江西中医药， 2015 , 46 ( 5 ): 64 - 70 .

汪会琴，胡如英，武海滨，等 . 2型糖尿病报告发病率研究进展 [J]. 浙江预防医学， 2016 , 28 ( 1 ): 37 - 39,57 .

赵晶，娄培安，张盼，等 . 2 型糖尿病患者焦虑和抑郁现状及危险因素的研究 [J]. 中国糖尿病杂志， 2014 , 22 ( 7 ): 615 - 619 .

曹裴娅，罗会强，侯利莎，等．中国 45 岁及以上中老年抑郁症状及影响因素研究 [J]. 四川大学学报：医学版， 2016 , 47 ( 5 ): 763 - 767 .

淳雪丽，蒲丽辉，王英，等．住院老年患者抑郁症状现况及相关因素研究 [J]. 现代预防医学， 2016 , 43 ( 8 ): 1453 - 1457 .

中华医学会糖尿病分会．中国2 型糖尿病防治指南(2013 年版) [J]. 中国糖尿病杂志， 2014 , 22 ( 8 ): 2 - 42 .

苏浩，仝小林，王皖洁，等．仝小林教授治疗糖尿病学术观点和经验 [J]. 中国医药指南， 2008 , 6 ( 24 ): 198 - 200 .

周珺，张黎，席红领，等．逍遥散加减对糖尿病合并抑郁症治疗作用的Meta分析 [J]. 中医学报， 2017 , 32 ( 10 ): 1878 - 1882 .

中华医学会糖尿病分会．中国2型糖尿病防治指南(2013年版) [J]. 中国医学前沿杂志：电子版， 2015 , 7 ( 3 ): 26 - 89 .

中华医学会精神病学分会 . 中国精神障碍分类与诊断标准第三版(精神障碍分类) [J]. 中华精神科杂志， 2001 , 34 ( 3 ): 184 - 188 .

中华人民共和国卫生部．中药新药临床研究指导原则 [M]. 北京：中国医药出版社， 1993 : 404 .

刘红梅，沈璐．从《内经》看中医对糖尿病的认识 [J]. 陕西中医， 2009 , 30 ( 12 ): 1638 - 1639 .

李洪基，石岩，杨宇峰，等．糖尿病的中医认识及其研究进展 [J]. 中国医药指南， 2016 , 14 ( 15 ): 34 - 35 .

宋薇，谢雯雯，范冠杰，等．运用中药治疗2型糖尿病 [J]. 中国实验方剂学杂志， 2014 , 20 ( 22 ): 207 - 211 .

张华，张静，李晓燕，等 . 2型糖尿病合并情绪障碍治疗研究进展 [J]. 医学综述， 2017 , 23 ( 10 ): 2002 - 2006 .

李肖，宫文霞，周玉枝，等．逍遥散中抗抑郁有效成分及其作用机制研究进展 [J]. 中草药， 2015 , 46 ( 20 ): 3109 - 3116 .

伍靓，吴奇，李晶，等．舍曲林联合逍遥散治疗产后抑郁症 [J]. 吉林中医药， 2014 , 34 ( 5 ): 469 - 471 .

王学，叶晓琳，刘小波，等．逍遥散抗抑郁作用的研究现状 [J]. 中国实验方剂学杂志， 2018 , 24 ( 16 ): 212 - 220 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Gynostemma pentaphyllum Alcohol Extract on Glucose and Lipid Metabolism Disorders in db/db Mice Based on Transcriptomics and Gut Microbiota

Mechanism of Action of Coptidis Rhizoma and Ophiopogonis Radix in Delaying Diabetic Nephropathy Based on EGFR/PI3K/Akt Signaling Pathway

Effect and Mechanism of Zuogui Jiangtang Yishen Prescription on Diabetic Kidney Disease in Rats via Regulation of MiRNA-27a/Wnt/β-catenin Pathway

Analysis of Potential Active Ingredients and Mechanism of Baihu Jia Renshentang in Treatment of Obesity Complicated with Type 2 Diabetes Mellitus

Mechanism of Zishen Qinggan Prescription in Improving Glucose and Lipid Metabolism in Type 2 Diabetes Based on Transcriptomics

Related Author

ZHU Yifei

DING Lei

LIU Wei

SUN Yahui

QIN Lingling

WU Lili

LIU Tonghua

LI Shaoyu

Related Institution

Key Laboratory of Traditional Chinese Medicine Health Care，Beijing University of Chinese Medicine

Beijing University of Chinese Medicine

Dongfang Hospital， Beijing University of Chinese Medicine

Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University

School of Pharmacy， Henan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰